Journal
JOURNAL OF PROTEOME RESEARCH
Volume 21, Issue 9, Pages 2224-2236Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jproteome.2c00332
Keywords
triple-negative breast cancer; glycoproteomics; cell surface targets; spheroids; xenograft; CRISPR-Cas9
Categories
Funding
- CCS Innovation Grant [705758]
- George Knudson and Helena Lam postdoctoral fellowship
- OGS Graduate student fellowship
- MBP Excellence OSOTF award
- Ontario Ministry of Health and Long-Term Care
- Kristi Piia CALLUM Memorial Fellowship in Ovarian Cancer Research
Ask authors/readers for more resources
This study identified a previously undescribed TNBC-enriched cell surface protein, PLXNB3, through N-glycoproteome analysis, and demonstrated its crucial role in the growth, invasion, and migration of TNBC cells.
Driven by the lack of targeted therapies, triple-negative breast cancers (TNBCs) have the worst overall survival of all breast cancer subtypes. Considering that cell surface proteins are favorable drug targets and are predominantly glycosylated, glycoproteome profiling has significant potential to facilitate the identification of much needed drug targets for TNBCs. Here, we performed N-glycoproteomics on six TNBCs and five normal control (NC) cell lines using hydrazide-based enrichment. Quantitative proteomics and integrative data mining led to the discovery of Plexin-B3 (PLXNB3), a previously undescribed TNBC-enriched cell surface protein. Furthermore, siRNA knockdown and CRISPR-Cas9 editing of in vitro and in vivo models show that PLXNB3 is required for TNBC cell line growth, invasion, and migration. Altogether, we provide insights into N-glycoproteome remodeling associated with TNBCs and functional evaluation of an extracted target, which indicate the surface protein PLXNB3 as a potential therapeutic target for TNBCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available